Article Text
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Q Does oestrogen plus progestogen reduce the risk of coronary heart disease (CHD) in postmenopausal women?
METHODS
Design:
randomised placebo controlled trial.
Allocation:
{concealed}*.
Blinding:
blinded {patients, clinicians, data collectors, outcome assessors, and monitoring committee}*.
Follow up period:
mean 5.6 years.
Setting:
{40 clinical centres in the US}*.
Patients:
16 608 postmenopausal women who were 50–79 years of age (mean age 63 y), had an intact uterus, and resided in the same geographic area for ⩾3 years.
Interventions:
1 daily tablet of oral conjugated equine oestrogen, 0.625 mg, plus medroxyprogesterone acetate (Prempro, Wyeth Ayerst, Philadelphia, PA, USA), 2.5 mg, (n = 8506) or placebo (n = 8102).
Outcomes:
CHD defined as acute myocardial …
Footnotes
For correspondence: Dr J E Manson, Division of Preventive Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA. jmansonrics.bwh.harvard.edu
Source of funding: National Heart, Lung, and Blood Institute.
A modified version of this abstract appears in ACP Journal Club.